Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.

NCT Number	NCT06328179
Lead Sponsor	Huai'an First People's Hospital Collaborators: Zhenjiang First People's Hospital, The First People's Hospital of Changzhou, The Affiliated Hospital of Xuzhou Medical University
Conditions	Acute Myeloid Leukemia
Enrollment	34 participants
Start Date	2022-05-24
Primary Completion	2027-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-03-25